Comparing Strategies for Lipid Lowering in Argentina: An Analysis from the CVD Policy Model–Argentina

• DOI: 10.1007/s11606-016-3907-8
• Publication Date: 2016-11-17T05:12:36Z
• Authors: Jonatan Konfino; Alicia Fernandez; Joanne Penko; Antoinette Mason; Eugenio Martinez; Pamela Coxson; David Heller; Andrew Moran; Kirsten Bibbins-D...; Eliseo J. Pérez-S...; Raul Mejía
• Keywords: Adult; Male; HDL; Cost-Benefit Analysis; Clinical Sciences; Argentina; hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor; Cardiovascular; LDL; 03 medical and health sciences; 0302 clinical medicine; prevention; cardiovascular disease; Risk Factors; General & Internal Medicine; 80 and over; Humans; coronary heart disease; Aged; Aged, 80 and over; Prevention; Cholesterol, HDL; statin; Cholesterol, LDL; Middle Aged; 3. Good health; Primary Prevention; Cholesterol; Heart Disease; Good Health and Well Being; Cardiovascular Diseases; Practice Guidelines as Topic; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors

In Argentina, the national guidelines for lipid control emphasize the use of relatively inexpensive low- or moderate-potency statins by patients at high risk (>20 %) of a cardiovascular event. The objective of this study was to compare the impact and costs of the current national CVD prevention guidelines with regard to morbidity and mortality in Argentina with the impact and costs of three strategies that incorporate high-potency statins.We used the CVD Policy Model-Argentina to model the proposed interventions. This model is a national-scale, state-transition (Markov) computer simulation model of the CVD incidence, prevalence, mortality, and costs in adults 35-84 years of age. We modeled three scenarios: scenario 1 lowers the risk threshold for treatment to >10 % according the Framingham Risk Score (FRS); scenario 2 intensifies statin potency under current treatment thresholds; and scenario 3 combines both scenarios by lowering the treatment threshold to ≥10 % FRS and intensifying statin potency.Scenario 1 would translate into 1400 fewer MIs and 500 fewer CHD deaths every year, a 3 % and 2 % reduction, respectively. Scenario 2 would lead to 2000 fewer MIs and 1000 fewer CHD deaths every year. Scenario 3 would result in the greatest reduction in MIs and CHD deaths, with 3400 fewer MIs and 1400 fewer CHD deaths every year, which translates to a 7 % and 6 % reduction, respectively. All scenarios were cost-effective if the cost of a high-potency statin pill was under US$0.25.Incorporating those individuals with greater than 10 % cardiovascular risk and the use of high-potency statins into Argentina's national lipid guidelines could result in fewer CHD deaths and events at a reasonable cost.